York Charles N II 4
4 · Day One Biopharmaceuticals, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
Day One (DAWN) COO/CFO York Receives Equity Awards
What Happened
Charles N. York II, Day One Biopharmaceuticals' Chief Operating Officer and Chief Financial Officer, was granted a total of 314,000 derivative equity awards on January 30, 2026: 188,000 option-type awards and 126,000 restricted stock units (RSUs). The reported acquisition price for both grants is $0.00 (i.e., no cash was paid at grant).
Key Details
- Transaction date: 2026-01-30 (Form 4 filed same day).
- Grants: 188,000 option units (derivative); 126,000 RSUs (derivative). Total = 314,000 awards.
- Reported cash consideration: $0.00 for both grants (award/compensation, not an open-market purchase).
- Shares owned after transaction: not specified in this Form 4 filing.
- Notable footnotes:
- F1: The 188,000 option vests 1/48th monthly starting Feb 28, 2026, contingent on continued service.
- F2–F4: Each RSU represents a right to one share; the 126,000 RSUs vest 1/16th quarterly (Feb 15, May 15, Aug 15, Nov 15) subject to continued service; RSUs do not expire but are either vested or canceled.
- Filing timeliness: Reported and filed for the same report date (no late filing indicated).
Context
These are compensation grants (awards) rather than open-market purchases or sales. They create a contingent right to shares that will vest over time based on service; they do not represent immediate ownership of shares unless and until vested/settled. For retail investors, award grants are common executive compensation and do not by themselves indicate buying or selling sentiment.
Insider Transaction Report
- Award
Stock Option (right to buy Common Stock)
[F1]2026-01-30+188,000→ 188,000 totalExercise: $11.16Exp: 2036-01-29→ Common Stock (188,000 underlying) - Award
Restricted Stock Units
[F2][F3][F4]2026-01-30+126,000→ 126,000 total→ Common Stock (126,000 underlying)
Footnotes (4)
- [F1]The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F3]The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F4]RSUs do not expire; they either vest or are canceled prior to the vesting date.